Binimetinib is a selective inhibitor of which kinases in which signaling pathway?

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards
From $25.99Unlock all

Study for the Pharmacology Presentation Drugs Test. Delve into flashcards and multiple choice questions with hints and explanations. Gear up for examination success!

Multiple Choice

Binimetinib is a selective inhibitor of which kinases in which signaling pathway?

Explanation:
Binimetinib targets MEK1 and MEK2, the kinases that phosphorylate and activate ERK in the MAPK signaling cascade. In this pathway, signals flow from Ras to RAF to MEK to ERK, and ERK drives transcriptional programs that promote cell proliferation. Blocking MEK1/2 with binimetinib stops ERK activation, curbing growth signals in tumors with MAPK pathway dysregulation. This specific target—MEK1/2 in MAPK—explains why this option is correct, while the other choices describe inhibitors of different pathways or different kinases (PI3K/AKT, RAF upstream, or JNK).

Binimetinib targets MEK1 and MEK2, the kinases that phosphorylate and activate ERK in the MAPK signaling cascade. In this pathway, signals flow from Ras to RAF to MEK to ERK, and ERK drives transcriptional programs that promote cell proliferation. Blocking MEK1/2 with binimetinib stops ERK activation, curbing growth signals in tumors with MAPK pathway dysregulation. This specific target—MEK1/2 in MAPK—explains why this option is correct, while the other choices describe inhibitors of different pathways or different kinases (PI3K/AKT, RAF upstream, or JNK).

More Multiple Choice Questions
Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy